Talzenna (Talazoparib) for Breast Cancer | MyBCTeam

Connect with others who understand.

sign up Log in
About MyBCTeam
Powered By

Talzenna is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with HER2-negative and germline BRCA-mutated breast cancer that is metastatic or locally advanced. Talzenna may also be referred to by its drug name, talazoparib.

Talzenna is a PARP inhibitor. Talzenna is believed to work by preventing cancer cells from being repaired.

How do I take it?
Prescribing information states that Talzenna is taken orally once per day.

Talzenna comes in capsule form.

Side effects
The FDA-approved label for Talzenna lists common side effects including tiredness or weakness, low blood cell counts, nausea, headache, diarrhea, vomiting, and hair loss.

Rare but serious side effects listed for Talzenna include bone marrow problems like myelodysplastic syndrome or acute myeloid leukemia, severely low blood counts, and fetal harm in pregnant women.

For more details about this treatment, visit:

Talzenna — Pfizer

Talzenna — RxList

How Do PARP Inhibitors Work in Cancer? — Dana Farber

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in